Newly formed NovoBiome becomes the latest firm to delve into the gut microbiome as it aims to harness Artificial Intelligence (AI) to develop Live Biotherapeutic Products (LBPs) that address liver conditions.
NovoBiome, which counts French public research bodies, The National Institute of Agricultural Research (INRAE) and the Bioaster as partners, now look to press ahead with its first LBP drug candidate that targets Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steato-Hepatitis (NASH).
“The microbiome is a fast growing and disruptive field of research that has the potential to revolutionize the diagnosis, prevention and treatment of liver diseases,” says Pierre-Yves Mousset, NovoBiome’s Chief Executive Officer.
To embed, copy and paste the code into your website or blog:
Welcome to our monthly digest of litigation and regulatory highlights impacting the personal care product and dietary supplement industry. April saw a re-emphasis on restriction of COVID-related claims in advertisements for supplements and therapies, developments in various class action cases, including a win for consumers challenging hand sanitizer’s claims of killing 99.99% of germs and a slew of new “natural” class actions, and finally a roller coaster ride for the FTC involving major blows and power moves.
Let’s take a look….
NAD
NAD determined that certain advertising claims made by Zarbee’s, Inc. for its cough products sufficiently identify that honey is the source of the cough soothing benefit and would not reasonably mislead consumers as to the reason for the product’s cough soothing efficacy. However, NAD found that other claims, which could reasonably suggest that the cough soothing benefit was
ANN ARBOR, MI / ACCESSWIRE / May 4, 2021 / ENDRA Life Sciences Inc. (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces the Company has recently been issued U.S. Patent
Novobiome: NovoBiome launched to revolutionize treatment of liver diseases by targeting the microbiome-gut-liver axis
the
targeting
microbiome NASH
after obesity and T
Paris
May 2021: NovoBiome ( the Company ), a drug discovery company focused on the critical nexus of liver, intestinal diseases and the gut microbiome, has been launched today by a team of world-leading experts in the fields of Microbiology and Artificial Intelligence. The new company will develop breakthrough Live Biotherapeutics Products (LBPs)
1 targeting the microbiome-gut-liver axis. NovoBiome is building a comprehensive, disruptive ex-vivo research and discovery platform to analyze the symbiotic relationship between the microbiota and the human intestine.
NovoBiome s first LBP drug candidate, ADC-001, targets potential first-in-class therapies for hepatic conditions such as Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steato-Hepatitis (NASH). NAFLD has become the most common cause of